{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:00:53Z","timestamp":1776744053623,"version":"3.51.2"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.xphs.2016.01.027","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T05:01:06Z","timestamp":1458018066000},"page":"2794-2803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Exploratory Investigation of the Limiting Steps of Oral Absorption of Fluconazole and Ketoconazole in Children Using an In Silico Pediatric Absorption Model"],"prefix":"10.1016","volume":"105","author":[{"given":"Rodrigo","family":"Cristofoletti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naseem A.","family":"Charoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2016.01.027_bib1","unstructured":"Food and Drug Administration (FDA). 2003. Guidance for Industry. Exposure-response relationships\u2013study design, data analysis and regulatory applications. Available at: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072109.pdf. Accessed January 10, 2016."},{"key":"10.1016\/j.xphs.2016.01.027_bib2","unstructured":"Food and Drug Administration (FDA). 2014. Guidance for Industry. General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological\u00a0Products. Available at: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm425885.pdf. Accessed January 10, 2016."},{"key":"10.1016\/j.xphs.2016.01.027_bib3","unstructured":"European Medicines Agency (EMA). 2007. Guideline on the Role of Pharmacokinetics in the Development of medicinal Products in the Paediatric Population.\u00a0Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003066.pdf. Accessed January 10, 2016."},{"key":"10.1016\/j.xphs.2016.01.027_bib4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1542\/peds.2010-3487","article-title":"Extrapolation of adult data and other data in pediatric drug-development programs","volume":"128","author":"Dunne","year":"2011","journal-title":"Pediatrics"},{"issue":"3 Suppl","key":"10.1016\/j.xphs.2016.01.027_bib5","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1067\/mai.2000.109419","article-title":"Impact of developmental pharmacology on pediatric study design: overcoming the challenges","volume":"106","author":"Kearns","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.xphs.2016.01.027_bib6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.xphs.2016.01.027_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2125.2006.02622.x","article-title":"Prediction of drug clearance in children from adults: a comparison of several allometric methods","volume":"61","author":"Mahmood","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2016.01.027_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1460-9592.2010.03323.x","article-title":"Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice","volume":"21","author":"Johnson","year":"2011","journal-title":"Paediatr Anaesth"},{"issue":"1","key":"10.1016\/j.xphs.2016.01.027_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/clpt.2012.64","article-title":"Physiologically based pharmacokinetic (PBPK) modeling in children","volume":"92","author":"Barrett","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2016.01.027_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","article-title":"Physiologically-based pharmacokinetics in drug development and regulatory science","volume":"51","author":"Rowland","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.xphs.2016.01.027_bib11","first-page":"e150","article-title":"Physiologically based pharmacokinetic modeling and simulation in pediatric drug development","volume":"22","author":"Maharaj","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3 Pt B","key":"10.1016\/j.xphs.2016.01.027_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ejpb.2013.04.015","article-title":"Application of in\u00a0vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients","volume":"85","author":"Batchelor","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2016.01.027_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2013.10.006","article-title":"Paediatric oral biopharmaceutics: key considerations and current challenges","volume":"73","author":"Batchelor","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"10.1016\/j.xphs.2016.01.027_bib14","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.clinthera.2012.09.014","article-title":"Summary of the NICHD-BPCA Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System (PBCS) Working Group","volume":"34","author":"Abdel-Rahman","year":"2012","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.xphs.2016.01.027_bib15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1208\/s12249-014-0084-0","article-title":"Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs","volume":"15","author":"Gandhi","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.xphs.2016.01.027_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","article-title":"BDDCS applied to over 900 drugs","volume":"13","author":"Benet","year":"2011","journal-title":"AAPS J"},{"issue":"8","key":"10.1016\/j.xphs.2016.01.027_bib17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/jphp.12411","article-title":"Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population","volume":"67","author":"Charoo","year":"2015","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2016.01.027_bib18","unstructured":"Pfizer Ltd. 2015. Summary of product characteristics. Diflucan tablets and oral\u00a0suspension. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019949s051lbl.pdf. Accessed January 10, 2016."},{"key":"10.1016\/j.xphs.2016.01.027_bib19","unstructured":"Agencia Nacional de Vigilancia Sanitaria (ANVISA). 2015. Nizoral comprimidos, Janssen-Cilag Framac\u00eautica Ltda, 2015. Available at: http:\/\/www.anvisa.gov.br\/datavisa\/fila_bula\/frmVisualizarBula.asp?pNuTransacao=7199492014&pIdAnexo=2185338. Accessed January 10, 2016."},{"issue":"12","key":"10.1016\/j.xphs.2016.01.027_bib20","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/jps.24181","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole","volume":"103","author":"Charoo","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2016.01.027_bib21","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s11095-009-9857-7","article-title":"Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs","volume":"26","author":"Clarysse","year":"2009","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2016.01.027_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1023\/A:1012102522787","article-title":"In\u00a0vitro permeability across Caco-2 cells (colonic) can predict in\u00a0vivo (small intestinal) absorption in man\u2014fact or myth","volume":"14","author":"Yee","year":"1997","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2016.01.027_bib23","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2016.01.027_bib24","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume of distribution predictions: understanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharm Res"},{"issue":"12","key":"10.1016\/j.xphs.2016.01.027_bib25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/lt.20519","article-title":"Changes in liver volume from birth to adulthood: a meta-analysis","volume":"11","author":"Johnson","year":"2005","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.xphs.2016.01.027_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/138920007779315053","article-title":"Scaling factors for the extrapolation of in\u00a0vivo metabolic drug clearance from in\u00a0vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver","volume":"8","author":"Barter","year":"2007","journal-title":"Curr Drug Metab"},{"issue":"5","key":"10.1016\/j.xphs.2016.01.027_bib27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s11095-006-9209-9","article-title":"Estimation of intragastric solubility of drugs: in what medium?","volume":"24","author":"Vertzoni","year":"2007","journal-title":"Pharm Res"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.01.027_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijpharm.2004.01.014","article-title":"Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers","volume":"274","author":"Ingels","year":"2004","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2016.01.027_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-198814010-00002","article-title":"Clinical pharmacokinetics of ketoconazole","volume":"14","author":"Daneshmend","year":"1988","journal-title":"Clin Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2016.01.027_bib30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/AAC.30.2.206","article-title":"Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers","volume":"30","author":"Huang","year":"1986","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.xphs.2016.01.027_bib31","article-title":"Different magnitude of positive food effects for two weak bases with similar BCS drug-related properties: what is happening in the intestinal lumen?","author":"Cristofoletti","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2016.01.027_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000238967","article-title":"Pharmacokinetics of fluconazole in normal volunteers","volume":"39","author":"Ripa","year":"1993","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1016\/j.xphs.2016.01.027_bib33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00003088-200645050-00006","article-title":"A\u00a0novel strategy for physiologically based predictions of human pharmacokinetics","volume":"45","author":"Jones","year":"2006","journal-title":"Clin Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2016.01.027_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction of oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2016.01.027_bib35","series-title":"Pharmacokinetic Profiling in Drug Research\u2014Biological, Physicochemical and Computational Strategies","first-page":"259","article-title":"Predicting the intestinal solubility of poorly soluble drugs","author":"Glomme","year":"2006"},{"issue":"11","key":"10.1016\/j.xphs.2016.01.027_bib36","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/cbdv.200900101","article-title":"Computational oral absorption simulation for low-solubility compounds","volume":"6","author":"Sugano","year":"2009","journal-title":"Chem Biodivers"},{"issue":"3","key":"10.1016\/j.xphs.2016.01.027_bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A\u00a0theoretical basis for a biopharmaceutic drug classification: the correlation of in\u00a0vitro drug product dissolution and in\u00a0vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2016.01.027_bib38","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation of various dissolution media for predicting in\u00a0vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm Res"},{"issue":"suppl 3","key":"10.1016\/j.xphs.2016.01.027_bib39","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","article-title":"Pharmacokinetics and tissue penetration of fluconazole in humans","volume":"12","author":"Brammer","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.xphs.2016.01.027_bib40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/bdd.1937","article-title":"A\u00a0meta-analysis of the effects of age and meal type on gastric emptying in premature neonates through to adults","volume":"36","author":"Bonner","year":"2015","journal-title":"Biopharm\u00a0Drug Dispos"},{"key":"10.1016\/j.xphs.2016.01.027_bib41","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1213\/00000539-199010000-00014","article-title":"Effects of duration of fasting on\u00a0gastric fluid pH and volume in healthy children","volume":"71","author":"Crawford","year":"1990","journal-title":"Anesth Analg"},{"key":"10.1016\/j.xphs.2016.01.027_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000244419","article-title":"Bile acid concentrations in serum and duodenal aspirates of healthy preterm infants: effects of gestational and postnatal age","volume":"71","author":"Boehm","year":"1997","journal-title":"Biol Neonate"},{"key":"10.1016\/j.xphs.2016.01.027_bib43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/BF02939169","article-title":"A\u00a0comprehensive study of duodenal bile salts in newborn infants and their relationship to fat absorption","volume":"149","author":"Glasgow","year":"1980","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.xphs.2016.01.027_bib44","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/adc.50.11.837","article-title":"Duodenal bile acids in infancy","volume":"50","author":"Challacombe","year":"1975","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.xphs.2016.01.027_bib45","first-page":"838","article-title":"Bile acids in infants and children","volume":"63","author":"Poley","year":"1964","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.xphs.2016.01.027_bib46","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/0016-5085(82)90061-0","article-title":"Biliary lipid composition in healthy and diseased infants, children, and young adults","volume":"82","author":"Heubi","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xphs.2016.01.027_bib47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/adc.54.2.131","article-title":"Duodenal bile acids in infants with protracted diarrhoea","volume":"54","author":"Challacombe","year":"1979","journal-title":"Arch Dis Child"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.01.027_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2010.04.048","article-title":"Specific aspects of gastro-intestinal transit in children for drug delivery design","volume":"395","author":"Bowles","year":"2010","journal-title":"Int J Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2016.01.027_bib49","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1517\/17425255.2012.698261","article-title":"Ontogeny of oral drug absorption processes in children","volume":"8","author":"Mooij","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.xphs.2016.01.027_bib50","unstructured":"World Health Organization (WHO). 2007. Position paper. Paediatric Age Categories to be Used in Differentiating Between Listing on a Model Essential Medicines List for Children. Available at: http:\/\/archives.who.int\/eml\/expcom\/children\/Items\/PositionPaperAgeGroups.pdf. Accessed January 10, 2016."},{"key":"10.1016\/j.xphs.2016.01.027_bib51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejps.2013.10.015","article-title":"Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs","volume":"57","author":"Bergstr\u00f6m","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2016.01.027_bib52","article-title":"Characterization of human duodenal fluids in fasted and fed state conditions","author":"Riethorst","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2016.01.027_bib53","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11095-011-0506-6","article-title":"Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults","volume":"28","author":"Psachoulias","year":"2011","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2016.01.027_bib54","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/AAC.00216-13","article-title":"Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in\u00a0vitro susceptibility breakpoints","volume":"57","author":"Sudan","year":"2013","journal-title":"Antimicrobial Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2016.01.027_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.1875-9114.1995.tb04331.x","article-title":"Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases","volume":"15","author":"Seay","year":"1995","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.xphs.2016.01.027_bib56","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2016.01.027_bib57","unstructured":"European Medicines Agency (EMA). 2010. Guideline on Investigation of Bioequivalence. Available at: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf. Accessed January 10, 2016."},{"issue":"2","key":"10.1016\/j.xphs.2016.01.027_bib58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/jac\/12.2.185","article-title":"Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man","volume":"12","author":"Daneshmend","year":"1983","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.xphs.2016.01.027_bib59","unstructured":"Food and Drug Administration 2015. Guidance for Industry: Waiver of In Vivo\u00a0Bioavailability and Bioequivalence Studies for Immediate-Release Solid oral\u00a0Dosage Forms Based on a Biopharmaceutical Classification System. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070246.pdf. Accessed January 10, 2016."},{"key":"10.1016\/j.xphs.2016.01.027_bib60","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/psp4.33","article-title":"Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK","volume":"4","author":"Wagner","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916003658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916003658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:45:51Z","timestamp":1718412351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916003658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0022354916003658"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2016.01.027","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploratory Investigation of the Limiting Steps of Oral Absorption of Fluconazole and Ketoconazole in Children Using an In Silico Pediatric Absorption Model","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2016.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}